An observational study in Severe Combined Immunodeficiencies (SCID), sponsored by Nantes University Hospital. Not yet recruiting at 1 site in France. Open to participants aged Up to 5 Years. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by Nantes University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Since September 2025, neonatal screening for severe combined immunodeficiency (SCID) has been generalized in France. These genetic disorders, which are asymptomatic at birth, cause severe immunodeficiency, exposing infants to serious infections (viral, bacterial, or fungal) as early as the first year of life. Without early treatment and management, infectious complications can be life-threatening.
Studies show that this screening improves survival and quality of life and reduces treatment costs by enabling intervention before complications arise.
In France, the Ministry of Health referred this matter to the Haute Autorité de Santé (HAS), which issued a favorable opinion in January 2022 via a ministerial decree (published on April 16, 2025) regarding the combined screening for DICS and spinal muscular atrophy. These authorizations follow the DEPISTREC study (2015-2017), which demonstrated the effectiveness of this screening: 190,517 children were screened, resulting in a reduction in DICS-related deaths.
The primary objective of the study will be to describe the underlying causes of T-cell lymphopenia identified in newborns through neonatal screening by quantifying TRECs on Guthrie cards. (SCID; variant SCID; syndromic T-cell deficiency; secondary T-cell deficiency; attenuated SCID; Omenn syndrome; immunosuppressive treatment in the mother; not found; isolated prematurity).
59 studies on the registry are indexed under Severe Combined Immunodeficiency; 14 are open to participants now.
This study's planned enrollment of 450 is above the median of 100 across 19 observational studies indexed under Severe Combined Immunodeficiency.
Browse Severe Combined Immunodeficiency studies →Nantes University Hospital is the lead sponsor of 839 studies on the registry; 189 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The target population consists of all children screened for SCID in France, that is, all children born in metropolitan France and the overseas territories whose parents consent to neonatal screening of their child using the Guthrie test.
Within this population, our cohort will include all children with a positive Guthrie card screening result confirmed by lymphocyte immunophenotyping performed during the first visit with a pediatric specialist. This will include the first baby screened on or after September 1, 2025 (the start date of neonatal screening for DICS in France) and will cover a 5-year period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Our cohort will include all children with a positive Guthrie test result, confirmed by lymphocyte immunophenotyping performed during their first visit with a pediatric specialist. This will include the first baby screened on or after September 1, 2025 (the start date of neonatal screening for DICS in France) and will cover a 5-year period.
Other: Data collection
The categories of data processed in the study database will be: * Clinical data * Laboratory data * Data related to newborn screening * Genetic data (only the results of genetic testing) * Care-related data (referral center, dates of tests, etc.)
Etiology of T-cell lymphopenia identified through newborn screening using TREC quantification on Guthrie cards
Time frame: Enrollment
Prevalence of SCID and severe T-cell lymphopenia in the screened population
Time frame: Enrollment
Description of the clinical management of newborns diagnosed with T-cell lymphopenia, whether SCID or non-SCID
Time frame: Enrollment
Describe the time frame for reporting test results
Time frame: Enrollment
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Aug 2035, 105 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Severe Combined Immunodeficiency →